Product Description
Tocilizumab (Actemra) is a biologic medication currently approved to treat adults with moderately to severely active rheumatoid arthritis (RA), adults with giant cell arteritis (GCA), and children ages two and above with Polyarticular Juvenile Idiopathic Arthritis (PJIA) or Systemic Juvenile Idiopathic Arthritis (SJIA). Biologic medications are proteins designed by humans that affect the immune system. Tocilizumab blocks the inflammatory protein IL-6. This improves joint pain and swelling from arthritis and other symptoms caused by inflammation. (Sourced from: https://www.rheumatology.org/I-Am-A/Patient-Caregiver/Treatments/Tocilizumab-Actemra)
Mechanisms of Action: IL6 Inhibitor
Novel Mechanism: No
Modality: Antibody
Route of Administration: Intravenous,Subcutaneous
FDA Designation: None *
Approval Status: Approved
Approved Countries: Algeria | Argentina | Australia | Austria | Belgium | Bosnia | Brazil | Canada | Chile | Colombia | Croatia | Cyprus | Czech | Denmark | Dominican Republic | Ecuador | Egypt | Estonia | European Medicines Agency | Finland | France | Germany | Greece | Hong Kong | Hungary | Iceland | India | Indonesia | Ireland | Israel | Italy | Japan | Jordan | Korea | Latvia | Lebanon | Lithuania | Luxembourg | Malaysia | Mexico | Morocco | Netherlands | New Zealand | Norway | Peru | Philippines | Poland | Portugal | Romania | Russia | Saudi Arabia | Singapore | Slovakia | Slovenia | South Africa | Spain | Sri Lanka | Sweden | Switzerland | Taiwan | Thailand | Tunisia | Turkey | Ukraine | United Arab Emirates | United Kingdom | United States | Uruguay | Venezuela | Vietnam
Approved Indications: None
Known Adverse Events: None
Company: Hoffmann-La Roche
Company Location: BASEL SWITZERLAND V8
Company CEO: Severin Schwan
Additonal Commercial Interests: None
Clinical Description
Countries in Clinic: Argentina, Australia, Austria, Belgium, Brazil, Canada, China, Colombia, Croatia, Czech Republic, Denmark, Estonia, Finland, France, Germany, Ghana, Greece, Hungary, India, Indonesia, Ireland, Israel, Italy, Japan, Korea, Mexico, Nepal, Netherlands, New Zealand, Pakistan, Poland, Portugal, Puerto Rico, Romania, Russia, Saudi Arabia, Serbia, Slovenia, South Africa, Spain, Sweden, Switzerland, Taiwan, Turkey, United Kingdom, United States, Vietnam
Active Clinical Trial Count: 58
Highest Development Phases
Phase 3: Acute Respiratory Distress Syndrome|Arthritis, Juvenile|Arthritis, Rheumatoid|COVID-19|Chills|Diffuse Large B-Cell Lymphoma|Dyspnea|Follicular Lymphoma|Giant Cell Arteritis|Influenza, Human|Pneumonia|Polymyalgia Rheumatica|Severe Acute Respiratory Syndrome
Phase 2: Adenocarcinoma|Astrocytoma|Bladder Cancer|Bone Cancer|Breast Cancer|Esophageal Cancer|Glioblastoma|Graves Disease|Heart Transplant|Hypertension|Kidney Transplant|Liver Cancer|Multiple Myeloma|Muscle Cancer|Myocardial Infarction|Non-Small-Cell Lung Cancer|Osteoarthritis, Knee|Pancreatic Cancer|Pancreatic Ductal Carcinoma|Shock, Cardiogenic|Transitional Cell Carcinoma|Triple Negative Breast Cancer|Type 2 Diabetes|Weight Gain|Weight Loss
Phase 1: Healthy Volunteers|Lymphoma, B-Cell|Lymphoma, Non-Hodgkin|Neutropenia|Purpura, Thrombocytopenic, Idiopathic|Thrombocytopenia
Trial |
Phase |
Trial Status |
Disease |
Primary Completion Date |
Probability of Success |
|---|---|---|---|---|---|
| PLYCOM | P2 |
Recruiting |
Multiple Myeloma |
2030-03-31 |
|
| SELECT-sJIA | P3 |
Recruiting |
Arthritis, Juvenile |
2029-06-01 |
|
| jRCT2031230402 | P3 |
Recruiting |
Arthritis, Juvenile |
2029-04-30 |
|
| M14-682 | P3 |
Unknown Status |
Arthritis, Juvenile |
2029-02-08 |